Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bill seeks to introduce ‘pull’ incentive for antibiotics

Two members of the House Energy and Commerce Committee introduced legislation that would create a new “pull” incentive pathway for priority antibiotics, providing manufacturers a transferable award that could be worth $1 billion or more. The bill, the Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018, aims

Read the full 468 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE